Skip to main content

Drug Interactions between fluconazole and fosphenytoin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

fluconazole fosphenytoin

Applies to: fluconazole and fosphenytoin

MONITOR CLOSELY: The concomitant use of fluconazole may increase serum hydantoin levels and risk of hydantoin toxicity. The mechanism is inhibition of CYP450 2C9 and 2C19 hepatic metabolism. In 10 healthy male volunteers, a mean increase in phenytoin AUC of 88% (with a range of 16% to 247%) was observed after 4 days of phenytoin administration (200 mg orally per day for 3 days followed by 250 mg IV once) with fluconazole (200 mg orally per day for 16 days) compared to phenytoin administration alone. Repeated concomitant administration of phenytoin (250 mg IV) and fluconazole (200 mg) also resulted in increased phenytoin AUC24 and Cmin by 75% and 128%, respectively.

MANAGEMENT: Close clinical monitoring of patient response, tolerance, and serum hydantoin concentrations is recommended whenever fluconazole is added, discontinued, or the dose changed. Patients should be advised to notify their doctor if they experience symptoms of toxicity (drowsiness, visual disturbances, change in mental status, nausea, or ataxia). A reduction in hydantoin dosage may be necessary.

References (14)
  1. Howitt KM, Oziemski MA (1989) "Phenytoin toxicity induced by fluconazole." Med J Aust, 151, p. 603-4
  2. Mitchell AS, Holland JT (1989) "Fluconazole and phenytoin: a predictable interaction." Br Med J, 298, p. 1315
  3. Grant SM, Clissold SP (1990) "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs, 39, p. 877-916
  4. Lazar JD, Wilner KD (1990) "Drug interactions with fluconazole." Rev Infect Dis, 12 Suppl 3, s327-33
  5. Vincent-Ballereau FN, Patey ON, Lafaix C (1990) "Fluconazole: review and situation among antifungal drugs in the treatment of opportunistic mycoses of human immuno-deficiency virus infections." Pharm Weekbl Sci, 13, p. 45-57
  6. Holechek MJ (1991) "Medication review: fluconazole." ANNA J, 18, p. 585-6
  7. Blum RA, Wilton JH, Hilligoss DM, et al. (1991) "Effect of fluconazole on the disposition of phenytoin." Clin Pharmacol Ther, 49, p. 420-5
  8. Morrow JD (1991) "Fluconazole: a new triazole antifungal agent." Am J Med Sci, 302, p. 129-32
  9. Touchette MA, Chandrasekar PH, Milad MA, Edwards DJ (1992) "Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man." Br J Clin Pharmacol, 34, p. 75-8
  10. Cadle RM, Zenon GJ III, Rodriguez-Barradas MC, Hamil RJ (1994) "Fluconazole-induced symptomatic phenytoin toxicity." Ann Pharmacother, 28, p. 191-5
  11. (2001) "Product Information. Dilantin (phenytoin)." Parke-Davis
  12. (2001) "Product Information. Diflucan (fluconazole)." Roerig Division
  13. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  14. Cerner Multum, Inc. "Australian Product Information."

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.